Ontology highlight
ABSTRACT: Background
Emicizumab, a bispecific antibody that mimics factor (F)VIII, has significantly improved hemophilia A management. Although emicizumab levels can be measured, tools for estimating the hemostatic efficacy of emicizumab are lacking. Thrombin generation (TG) assays can distinguish bleeding phenotypes in persons with hemophilia A on FVIII prophylaxis and may also be used during emicizumab therapy.Objectives
To assess the association between TG parameters, emicizumab levels, and bleeding in patients on emicizumab therapy.Methods
A single-center longitudinal cohort study was conducted, with samples collected during the steady-state phase of emicizumab therapy. TG was measured using tissue factor (TF; TF-TG, 1 pM) and FXIa (FXIa-TG, 200 pM). Emicizumab concentrat
SUBMITTER: van der Zwet K
PROVIDER: S-EPMC11754509 | biostudies-literature | 2025 Jan
REPOSITORIES: biostudies-literature